COMMUNIQUÉS West-GlobeNewswire

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
26/03/2026
Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq. Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System ( [...]
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
26/03/2026
Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company. Full year 2025 revenues were $44.1 million up 35.0% from full year 2024 revenues. This was an all-time [...]
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
26/03/2026
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with [...]
Galapagos Announces Nomination of Gino Santini to its Board of Directors
26/03/2026
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership [...]
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
26/03/2026
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
26/03/2026
LOUISVILLE, Ky., March 26, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant [...]
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
26/03/2026
WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
26/03/2026
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT [...]
Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
26/03/2026
New Leadership to Accelerate Market Adoption and Scale Commercial Growth GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2025 Financial Results on March 31, 2026
26/03/2026
FREDERICK, Md., March 26, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2025
26/03/2026
Châtillon, France, le 26 mars 2026 DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
26/03/2026
Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025 In February, Spero’s licensing partner, [...]
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
26/03/2026
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the [...]
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
26/03/2026
-- Zola ® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination -- -- Exercise of preferred investment options yields $2.1 million gross proceeds -- DALLAS, [...]
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
26/03/2026
CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1- [...]
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2025 le 31 mars 2026
26/03/2026
Conférence téléphonique et diffusion en direct sur Internet le mercredi 1er avril 2026 à 14h00 CEST / 8h00 EDT PARIS et CAMBRIDGE, Mass., 26 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – [...]
XORTX Announces Change of Effective Date of Share Consolidation
26/03/2026
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
26/03/2026
Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25 Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to [...]

Pages